|Bid||123.08 x 900|
|Ask||123.15 x 1400|
|Day's Range||121.98 - 123.78|
|52 Week Range||114.94 - 137.73|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||1.17|
|Expense Ratio (net)||0.24%|
With growth stocks surging again in 2018, it is not surprising that mid-cap names are getting in on that act. For example, the iShares Russell Mid-cap Growth Index (NYSEARCA: IWP) is up nearly 13% year-to-date. ...
Abiomed’s (ABMD) net income has grown at a three-year and five-year average of 95.1% and 120.4%, respectively. The company’s pre-tax margin grew from 10.7% in 2013 to 20.5% in 2017. ABMD beat the medical device industry and the S&P 500 between 2013 and 2017. The market cap gained 680% between 2013 and 2017.
After a prolonged calm period, volatility roared back into the market with the sharp rise in Treasury yields, which led to the bloodbath in the stock market this week. This pushed the major indices into the red territory for the year and in the correction zone from the latest peak.Source: Investment Zen via Flickr (Modified)